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Abstract
Accurate identification of human papillomavirus (HPV)-types in cervical cancer tissue may be important for tailoring tests for primary
screening and types to be included in a vaccine. The aim of this study was to compare test-performance of a 45-type HPV
deoxyribonucleic acid (DNA)-test with a 9-type HPV messenger ribonucleic acid (mRNA)-test in cervical cancer tissues.
In a case-seriesdesign188womenwithdiagnosedcervical cancer during theperiodJanuary2008 toJuly 1, 2011at theGynaecological
Oncology Unit, University of Pretoria, South Africa were recruited to the study. After cases with negative internal controls for DNA/mRNA
detection (n=18) and unconfirmed histology (n=3) of cervical cancer were excluded, 167 women remained eligible for analysis. We
compared 45 DNA-types detected through general primer (GP)5+/6+ polymerase chain reaction (PCR) and reverse line blot (RLB)
genotyping with a modified version of the mRNA test PreTect HPV-Proofer detecting 9 genotypes (16, 18, 31, 33, 35, 45, 51, 52, 58).
Histological types were 92.2% squamous cell carcinoma, 4.8% adenocarcinoma, and 3.0% adenosquamous carcinoma. Overall,
HPV was detected in 95.2% (159/167) of specimens. The DNA- and mRNA tests each rendered 153/167 (91.6%) HPV positive
results. When restricting the analysis to the 9 high-risk HPV-types included in the mRNA test, 91.6% (153/167) and 88.0% (147/167)
were positive by the mRNA- and DNA-tests (P= .28), respectively. After hierarchical categorization of 9 comparable types, we found
concordance in 66 of 67 specimens for HPV16, 25 of 27 specimens for HPV18, 19 of 21 specimens for HPV45, and only in 33 of
45 for HPV31, 33, 35, 51, 52, 58. The positivity rate for the HPV types 16, 18, and 45 and the positivity rate for HPV 16, 18, 45, 33 and
35 by both tests was 66% to 68% and 80% to 83%, respectively.
Overall and when considering established high-risk types, the mRNA test has at least as high detection rate as the DNA test. The
mRNA test can be an appropriate research tool to describe causative HPV-types in cervical cancer tissue for health care planning
purposes.
Abbreviations: bp= base pairs, CIN3 = cervical intraepithelial neoplasia grade 3, DNA = deoxyribonucleic acid, dsDNA= double
strand DNA, EIA= enzyme immunoassay, GP= general primer, HIV= human immunodeficiency virus, HPV= human papillomavirus,
IARC = international agency for research on cancer, ICC = invasive cervical cancer, ISC = intrinsic sample control, ISH = in situ
hybridization, ISM = Department of Community Medicine (Norwegian: Institutt for samfunnsmedisin), mRNA = messenger
ribonucleic acid, NASBA = nucleic acid sequence based amplification, ORF = open reading frame, PCR = polymerase chain
reaction, pRb= protein retinoblastoma, RLB= reverse line blot, SCC= squamous cell carcinoma, SPF= short PCR fragment, SPSS
= Statistical Package for the Social Sciences.
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Cervical cancer ranks in women as the fourth most common
cancer worldwide.[1] In South Africa, cervical cancer is the most
frequent cancer in women aged 15 to 44 years and the second
among women of all ages.[2]
Human papillomavirus (HPV) infection is the necessary, but
not sufficient, cause for cervical cancer.[3–5] Persistent HPV
infection is the most important risk factor for cervical cancer.[6]
HPV-targeted screening programs and HPV vaccination are
implemented in many countries to reduce cervical cancer
incidence, morbidity, and mortality.[7] Knowledge of HPV type
distribution in cervical precancerous and cancer histology is
important to prioritize HPV types in future HPV prophylactic
vaccines and HPV-based screening tests.[8]
Evaluation of the carcinogenic properties of HPV lacks
longitudinal studies with cervical cancer as endpoint.[9,10]
Meta-analysis on prevalence of HPV types detected in cervical
cancer reutilize the same studies,[5,8,11,12] which lack consistency
in HPV detection methods applied, number of HPV types
targeted, and often validation of histological diagnoses are
missing. In addition, most studies report all HPV types identified
Rad et al. Medicine (2017) 96:47 Medicinewithout a hierarchical approach to the types that are major
drivers in the oncogenesis. This may overestimate the role of the
low prevalent types, which often are appearing as coinfections in
cervical cancer tissue. Knowledge on the biological mechanisms
of HPV carcinogenicity is limited to basic research applied mostly
to HPV16- and less to HPV18-infected cell lines,[13–15] while
evidence from basic research on the carcinogenic properties of
other HPV types is lacking.
HPV tests differ in their clinical performance, sensitivity, and
specificity.[16–20] The characteristics of HPV tests are different in
targeted nucleic acid (deoxyribonucleic acid [DNA] or ribonu-
cleic acid [RNA]), targeted genes in HPV genome, and the ability
of separate genotyping.[21] The general primer (GP)5+/6+
polymerase chain reaction (PCR)-enzyme immunoassay (EIA)
(polymerase chain reaction-reverse line blot) assay targets the
L1 region of HPV DNA with no ability to report genotypes
separately, while PreTect HPV-Proofer targets E6/E7 regions of
HPV messenger ribonucleic acid (mRNA) and can detect types
16, 18, 31, 33, and 45, separately.[21]
DNA-basedHPV tests detect the presence ofHPV at DNA level
and not necessarily the transcriptional and translational activity
of the HPV DNA. The oncogenic activity of HPV type 16 is
known to be through the expression of viral genes E6 and E7,
following inactivation of cell tumor suppressor proteins p53 and
protein retinoblastoma (pRB).[22] The E6 and E7 gene expression
from HPV types 16, 18, 31, 33, and 45 has been confirmed in the
majority of cervical carcinomas.[23] The mRNA-based HPV test
detects the E6 and E7 oncogenic expression of HPV and it is
based on the real-time multiplex nucleic acid sequence-based
amplification (NASBA) assay called PreTect HPV-Proofer.[24] On
the other hand, there are several methods to test the presence of
HPV DNA including PCR, reverse line blot (RLB) sequencing, in
situ hybridization (ISH) and EIA, with PCR being the most
commonly applied method for HPV DNA analysis. The PCR-
based tests are using either consensus PCR primers that can cover
a range of DNA types or type-specific PCR primers that work for
specific genotypes. Depending on PCR primers, the size of the
PCR-amplified fragment differs; for instance, the amplified
fragment for MY09/11 is about 450 base pairs (bp) while the
GP5/6 fragment size is approximately 140bp.[25] The short PCR
fragment primers (SPF10), which were developed for universal
detection of HPV, target only 65bp of the L1 open reading frame
(ORF) in at least 43 HPV genotypes.[26,27] The SPF10 primers are
more sensitive than other primers, especially when multiple HPV
genotypes are present.[27,28] It is noticeable that as the applied
primers in HPV DNA test have fewer base pairs, the ability of the
test to detect the presence of HPV DNA in tumor tissues and,
consequently the test sensitivity, increases. Conversely, the
specificity of these tests drops and it becomes less informative
on the oncogenic properties. The DNA-based HPV tests detect
the HPV viral DNA presence, which might be in transient phase
and not active oncogenes while mRNA test positivity implies
continuous expression of the viral E6 and E7 oncogenes.
The aim of this study was to compare the test-performance of a
45-type HPV DNA-test with a nine-type HPV mRNA-test in
cervical cancer tissues.2. Materials and methods
This study was performed in collaboration between the Institute
of Community Medicine (ISM) and Department of Clinical
Pathology, Faculty of Health Sciences, University of Tromso,
Norway; PreTect AS, Klokkarstua, Norway; and the Gynecologic2
OncologyUnit, Departments of Obstetrics andGynaecology and
Anatomical Pathology, University of Pretoria, South Africa. The
Research Ethics Committee of the Faculty of Health Sciences of
the University of Pretoria reviewed and approved the study
protocol (27/2008, 108/2008, 189/2012). All the participants
gavewritten informed consent. At the time of presentation for the
evaluation and staging of disease, tissue biopsies were taken for
histological confirmation of the diagnosis of invasive epithelial
cervical cancer and HPV analysis. Two adjacent punch biopsies
were taken at the 3 o’clock and 9 o’clock positions. One biopsy
from each position was preserved in formalin and sent to the
Department of Anatomical Pathology at the University of
Pretoria for histological diagnosis. Two pathologists reviewed
all histological diagnosis until consensus was reached.
The second biopsy from each position was preserved in a
standard commercially available methanol-buffer solution,
PreTect TM (PreTect AS) and shipped to Norway for HPV
DNA and mRNA analyses. These biopsies were cut in small
pieces on a cold metal block using a scalpel and transferred to a
microcentrifuge tube prior to addition of 1 mL lysis buffer
(NucliSens, BioMerieux, France), followed by homogenization
for 30seconds using a pellet pestle and incubation at 37°C for
30 minutes. Total nucleic acids (DNA/RNA) were extracted
using NucliSENS miniMAG (BioMerieux, 200297, Boxtel, The
Netherlands) according to the manufacturer’s instructions and
kept at 70°C prior to DNA/mRNA testing performed on the
same extracts. All laboratory testing was performed blindly.
Human papillomavirus DNA analysis, testing for 39 individual
types (HPV 6, 11, 16,18, 26, 30, 31, 33, 34, 35, 39, 40, 42, 43,
44, 45, 51, 52, 53, 54,55, 56, 57, 58, 59, 61, 64, 66, 67, 68, 69,
70, 71, 72, 73, 81, 82/MM4, 82/IS39, and CP6108) and 6 rare
HPV types (HPV32, 83, 84, 85, 86, and JC9710) as a pool, was
performed onGP5+/6+ polymerase chain reaction products using
RLB assay.[29,30] Polymerase chain reaction toward the B-globin
gene was included as DNA control for all HPV-negative samples.
Human papillomavirus mRNA E6/E7 analysis, testing for 9
individual HPV types (HPV 16, 18, 31, 33, 45, 35, 51, 52, 58)
was performed using an extended version of PreTect HPV-
Proofer, a diagnostic kit for the qualitative detection and direct
typing of E6/E7 mRNA from 5 HPV types[16,18,31–33] plus 4
additional HPV types (35,51,52,58). The kit is based on real-time
NASBA technology combining nucleic acid amplification and
simultaneous detection with specific Molecular Beacon probes.
NASBA is an enzymatic 1-step amplification process that is able
to specifically amplify RNA in a double-strand DNA (dsDNA)
background under isothermal conditions (41°C). By using an
RNA T7-polymerase promoter to generate multiple RNA
products at 41°C, double-stranded DNA is not denatured and
consequently not amplified, hence the presence of genomic
dsDNA will not cause false positives.[31]
Intrinsic sample control (ISC) directed against mRNA from a
human housekeeping gene is included in the kit to assess specimen
quality and reveal possible factors that may inhibit the
amplification, hereby monitoring the entire test process.
Standardized artificial oligonucleotides corresponding to the
respective viral sequences were used as positive controls for each
of the HPV types and water as negative control. The PreTect
Analysis Software (PAS, PreTect AS) performed all assay
validation, where all controls and specimen ISC results have to
be valid to report an HPV result.
A total of 188 patients with invasive cervical cancer referred to
the gynaecologic oncology unit at the University of Pretoria
during the period January 1, 2008 to July 31, 2011were recruited
Table 1










Unknown 0 0.8 0.6
Negative 18.4 69.8 58.1
Positive 81.6 29.5 41.3
Histology
Squamous carcinoma 100 89.9 92.2
Adenocarcinoma 0 6.2 4.8
Adenosquamous carcinoma 0 3.9 3.0
HIV = human immunodeficiency virus.
Rad et al. Medicine (2017) 96:47 www.md-journal.comto the study. We excluded women without validated histological
diagnosis of cervical cancer (n=3) and samples with low quality
of genomic material by using ISC (n=18). The final study
population comprised 167 patients.
All data analyses were done in SPSS, version 24.0.We applied a
2-tailed 2-proportion Z-test to compare positivity rates between
the tests with significance level P< .05.
We applied a hierarchical approach where one type is counted
only once by decreasing prevalence order of HPV types in our
own data.3. Results
The majority of patients (77.2%) were older than 40 years (range
25–89 years), and 41.3% (69/167) were HIV positive. Histology
results showed 92.2% (154/167) cases of squamous cell
carcinoma (SCC), 4.8% adenocarcinoma, and 3.0% adenosqu-
amous carcinoma. Among women less than 40 years, 81.6% (31/
38) were HIV-positive. All women in this age group had SCC.
Among women older than 40 years, 29.5% (38/129) were HIV-
positive, and 90% (116/129) were diagnosed with SCC (Table 1).
Considering both the DNA- and mRNA test results, 95.2%
(159/167) of the specimens were HPV positive in at least 1 test,
while the DNA- and the mRNA-tests each rendered 91.6% (153/
167) HPV positive results. In 7.8% (13/167) specimens
HPV were detected only by the DNA test and similarly inTable 2



















DNA = deoxyribonucleic acid, HIV = human immunodeficiency virus, HPV = human papillomavirus, m
3
7.8% (13/167) specimens, HPV were detected only by mRNA
test. There were 11 double infections detected by mRNA analysis
and 4 double infections detected by DNA analysis.
When analyzing the 9 most prevalent HPV types hierarchically
(16>18>45>35>33>52>31>58>51), 91.6% (153/167) were
positive by themRNA test and 88.0% (147/167) by the DNA-test
(P= .28). In total, 83.8% (140/167) were positive for the same
HPV type by both tests, while there were 26 discordant results.
We found concordance in 66 of 67 cases of HPV16, 25 of 27
cases of HPV18, 19 of 21 cases of HPV45, 15 of 18 cases of
HPV35, and 18 of 27 cases of HPV types 33, 52, 31, 58, and 51
collectively. HPV types 30, 56, 69, 73, 82were not included in the
mRNA test, which added 6 more positive cases by the DNA test
(Table 2, lower panel).
Among the HPV-negative cases, 8 biopsies were negative in
both the tests. In addition, 6 biopsies were negative only by the
DNA test and 6 biopsies were negative only by the mRNA test.
The positivity rate for the HPV types 16, 18, and 45 and the
positivity rate for HPV 16, 18, 45, 33, and 35 by both tests
summarized to 66% to 68% and 80% to 83%, respectively.
Thirty-eight women were less than 40 years of age, among whom
31 women were HIV-positive. Twenty-nine of these 31 HIV
infected women tested positive for HPV by both tests; 29 and 26
out of 31 HIV positive women were positive for the 9 high risk
types by the mRNA- and the DNA-test, respectively. Table 3
displays a more complete comparison of the concordance and
discordance in DNA/mRNA analyses among HIV negative and
positive women. Positivity rates of type-specific HPV by DNA-
and mRNA-tests did not differ in any of the comparisons (data
not shown).4. Discussion
In this case-series of 167 women diagnosed with cervical cancer,
95.2% (159/167) were HPV positive in at least 1 test. There were
no differences in overall comparisonwith types detected by the 45
types DNA test (91.6%) and the 9 types mRNA test (91.6%).4.1. Overall positivity rate
In most prevalence studies of HPV detection in cervical cancer






















RNA = messenger ribonucleic acid.
[8]
Table 3
Comparison in DNA/mRNA analysis of type-specific HPV detection in HIV negative/positive women stratified by age.
HIV negative N=7 HIV positive N=31
Age HPV type mRNA DNA mRNA DNA
25–39 y Negative 0 0 2 2
16 4 4 6 6
18 1 1 10 9
45 1 1 6 5
35 1 1 3 3
33 0 0 0 0
52 0 0 1 0
31 0 0 1 2
58 0 0 0 0
51 0 0 2 1
30 NA 0 NA 0
56 NA 0 NA 0
69 NA 0 NA 1
73 NA 0 NA 1
82 NA 0 NA 1
HIV negative N=90 HIV positive N=38
HPV type mRNA DNA mRNA DNA
40–89 y Negative 10 10 2 2
16 39 39 16 17
18 12 12 4 3
45 6 5 8 8
35 11 11 1 2
33 5 5 4 1
52 4 3 2 2
31 2 2 0 0
58 1 1 0 2
51 0 0 1 0
30 NA 1 NA 0
56 NA 1 NA 0
69 NA 0 NA 0
73 NA 0 NA 0
82 NA 0 NA 1
DNA = deoxyribonucleic acid, HIV = human immunodeficiency virus, HPV = human papillomavirus, mRNA = messenger ribonucleic acid.
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Our overall 95.2% HPV positivity rate was higher than in
another African study (Ghana, Nigeria, and South Africa
(90.4%))[34] and similar to what has been reported from a
European study that tested for HPV DNA in cervical cancer
tissue.[32] Another study from Norway found an overall 97%
HPV positivity rate in tissue from squamous cell carcinoma,[23]
while the type-specific PCR primers, consensus Gp5+/6+ PCR
primers for HPV DNA, and 8-types E6/E7 mRNA test had equal
92% positivity rates.[23] Similarly, a study from India reported an
overall 91.7% positivity rate of HPV in cervical cancer specimens
with no difference in positivity rate between MY09/11 L1
consensus PCR applied HPV DNA test and the PreTect HPV-
Proofer (5 types).[35] A meta-analysis summarizing results from
case-series of HPV prevalence in cervical cancer tissue, regardless
of method and number of methods used, demonstrated overall
87% HPV DNA positivity, reaching 94% in cervical cancer
specimens from Africa.[8]4.2. HPV type distribution
Our analyses are based on a hierarchical approach where each
type is counted only once by order of decreasing prevalence. We
found the same order of prevalence as summarized by Smith et al4
in 5 studies fromAfrica, except for HPV 33 andHPV 52. Smith
et al[8] counted each type more than once if they occurred as
double/tripled infections.However,we found a lower prevalence of
HPV 16, similar prevalence of HPV 18, and higher prevalence for
HPV 45, 33, and 52 than displayed by Smith et al[8] and in another
study fromGhana,Nigeria, and SouthAfrica.[34] Comparedwith a
European study on prevalence of HPV types in cervical cancer
tissue, we again found a lower prevalence ofHPV16, and relatively
higher prevalence of HPV 45, 35, and 52.[32]4.3. Prevalence, persistency, and progressive ability
Evaluation of the carcinogenic properties of HPV suffers from the
lack of long-term prospective studies with cervical cancer as
endpoint.[9,10] Most of the reviews and meta-analysis considered
prevalence from case-control or case-series studies.[5,8,11,12]
Although HPV types may differ by order of magnitude in risk
for cervical cancer,[36] the International Agency for Research on
Cancer (IARC) did not rank the HPV types according to this risk,
except for types 16 and 18. They simply concluded that HPV
types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 are
carcinogenic in the human cervix.[36,37]
In cervical carcinogenesis, genotype-specific HPV persistence is
associated with higher risk of cervical cancer than transient HPV
[10,38–40]
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some of the HPV types that are classified by the IARC and other
above-mentioned studies as high risk or carcinogenic, had no or
little potentiality for progression to high-grade cervical lesions
and cancer.[10,41–45]
HPV types 16, 18, and 45 have been detected more frequently
in invasive cervical cancer (ICC) than cervical intraepithelial
neoplasia grade 3 (CIN3) cases, suggesting differences in type-
specific risks for progression and the necessity of treatment for
cervical lesions related to these types.[8,32,33] This, together with
the narrow median age differences between CIN3 and SCC in
women diagnosed with HPV types 16, 18, and 45, indicates the
progressive nature of HPV types 16, 18, and 45.[32]4.4. HPV types distribution among HIV positive/negative
women
In this study, similar to other studies from Mozambique,[46]
Kenya,[47] and South Africa,[47] we did not detect significant
differences in positivity rates of HPV types by HIV status. Since
cell-mediated immunity is crucial in clearing HPV infection
and for regression of cervical lesions,[48] we expected a different
HPV-type distribution. Among immunocompromised women
“low risk types” could becomemore “oncogenic,” but our results
did not confirm such a theory. Lack of knowledge on the time of
HIV acquisition is another difficulty in determining the oncogenic
potential of HPV types by HIV status.[47] In case the HIV
infection took place after HPV infection and, especially, in the
last years before cervical cancer development, the HIV-associated
immune impairments would not affect the responsible HPV
type.[47] Moreover, it is supposed that micronutrient deficiency
and chronic infections in African countries may also suppress the
immune system and, consequently, fade the association between
type-specific HPV infection and HIV status.[49]4.5. Strengths
We consider the application of NASBA technology as a strength
in mRNA detection method. This technology amplifies RNA
under isothermal conditions, which avoids denaturing and, in
turn, amplification of double stranded DNA. Therefore, the false
positives from the presence of genomic dsDNA in the background
of mRNAmay be prevented.[31] The usage of 2 different methods
for HPV detection, together with the high concordance (84%) in
type detection between methods, is considered another strength.
In addition, we consider the hierarchical approach in
performing analyses for multiple infection cases as a strength.
The hierarchical analysis of single infections avoids overestima-
tion of the less prevalent types in cervical cancer specimen.
The results from hierarchical studies provided more accurate
information on the role of HPV16/18 compared with other
oncogenic HPV types for the risk of CIN3 and cancer.[43,45]4.6. Limitations
In a global perspective, our sample size may be considered a
limitation,[8,32] however, from a regional or national perspective,
our sample size is above average of published studies. Some HPV
types that tested positive using the DNA test were not covered by
the mRNA test and thus could not be confirmed as carcinogenic.
This could be a limitation for the mRNA detection and also type
specific comparisons. However, these HPV-types are considered
to have low oncogenic properties.5
5. Conclusion
Overall and when considering established high-risk types, the
mRNA test has at least as high a detection rate as the DNA test.
The mRNA test can be an appropriate research tool to describe
causative HPV-types in cervical cancer tissue for health care
planning purposes.Acknowledgments
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